RESEARCH DESK
Hormone research, decoded and labeled.
New trials, approvals and guideline changes in menopause, testosterone and thyroid care, each with an evidence label, a plain-language summary and a link to the primary source. Updated every two weeks.
Regulatory
·
FDA moves to remove boxed warnings from menopause hormone therapy
HHS and the FDA announced they will remove boxed warnings about cardiovascular disease, breast cancer and probable dementia from more than 20 menopausal hormone therapy products, while keeping the warning about endometrial cancer for systemic estrogen used alone.
Regulatory action
Approvals
·
FDA approves elinzanetant (Lynkuet), a dual NK1/NK3 blocker for hot flashes
The FDA approved Bayer’s elinzanetant, a once-nightly non-hormonal capsule for moderate to severe hot flashes and night sweats caused by menopause.
Phase 3 RCTs
Clinical Trials
·
TRAVERSE: testosterone does not raise major cardiac events in men with hypogonadism
In 5,246 men aged 45 to 80 with low testosterone and existing or high risk of cardiovascular disease, testosterone gel was noninferior to placebo for heart attack, stroke and cardiovascular death.
Human RCT
Cohort Studies
·
SWAN: frequent hot flashes last a median of 7.4 years
The Study of Women’s Health Across the Nation followed 1,449 women with frequent hot flashes or night sweats and found they lasted a median of 7.4 years in total, continuing a median of 4.5 years after the final menstrual period.
Prospective cohort
HOW WE COVER RESEARCH
Evidence, labeled by design.
01
Primary sources first
Every update links to the trial publication, FDA document or guideline it describes, not to press coverage of it.
02
Labeled by study design
Randomized trials, cohort studies and regulatory actions answer different questions, so every update carries its evidence label.
03
Corrected in the open
When new data change the picture, we update the page and say what changed and when, instead of quietly rewriting it.
THE YOUTHFUL HORMONES BRIEF
Get every update in your inbox.
Educational content only. Unsubscribe anytime.